A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies

Pediatric Blood and Cancer

Volumn 49, Issue 3, 2007, Pages 261-265

  Gilheeney, Stephen W ^a   Lyden, David C ^a   Sgouros, Shirley ^a   Antunes, Nuno ^a   Gerald, William ^a   Kramer, Kim ^a   Lis, Eric ^a   Meyers, Paul ^a   Rosen, Nancy ^a   Thaler, Howard T ^a   Trippett, Tanya ^a   Wexler, Leonard ^a   Dunkel, Ira J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Angiogenesis; Pediatric oncology; Thalidomide; Therapeutics

Indexed keywords

ANGIOGENESIS INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCUSATE SODIUM; THALIDOMIDE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DAYTIME SOMNOLENCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HODGKIN DISEASE; HUMAN; INFECTION RISK; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECURRENT CANCER; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; NEOPLASMS; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 34547747328     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21045     Document Type: Article

References (29)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
2. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194-1201.
3. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8:1160-1161.
4. Franks M, Macpherson G, Figg W. Thalidomide. Lancet 2004;363: 1802-1811.
5. D'Amato R, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Nad Acad Sci USA 1992;91:4082-4085.
6. Moreira A, Sampaio E, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factro alpha by enhancing mrna degradation. J Exp Med 1993;177:1675-1680.
7. Sampaio E, Sarno E, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699-703.
8. Keifer J, Guttridge D, Ashburner B, et al. Inhibition of nf-kb activity by thalidomide through suppression of ikb kinase activity. J Biol Chem 2001;276:22382-22387.
9. Bessmertny O, Pham T. Thalidomide use in pediatric patients. Ann Pharmacother 2002;36:521-525.
10. Palencia G, Arrieta O, Rios C, et al. Effect of thalidomide in different tumors in rodents. J Exp Ther Oncol 2002;2:158-162.
11. Marx G, Pavlakis N, McCowatt S, et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol 2001;54:31-38.
12. Cole C, Rogers P, Pritchard S, et al. Thalidomide in the management of chronic graft-versus-host disease in children folowing bone marrow transplantation. Bone Marrow Transplant 1994;14:937-942.
13. Strupp C, Germing U, Scherer A, et al. Thalidomide for the treatment of idiopathic myelofibrosis. Eur J Haematol 2004;72: 52-57.
14. Dal Lago L, Richter M, Cancela A, et al. Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. Invest New Drugs 2003;21:359-366.
15. Reiriz A, Richter M, Fernandes S, et al. Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res 2004;14:527-531.
16. Kakeji Y, Teicher B. Pre-clinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997;15:39-48.
17. Fine H, Wen P, Maher E, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 2003;21:2299-2304.
18. Hwu W, Krown S, Menell J, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003;17:3351-3356.
19. Baumann F, Bjeljac M, Kollias S, et al. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neurooncol 2004;67:191-200.
20. Chao N, Parker P, Niland J, et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-versus-host disease. Biol Blood Marrow Transplant 1996;2:86-92.
21. Tran H, Blumenschein GJ, Lu C, et al. Clinical and pharmacokinetic study of tnp-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 2004;54:308-314.
22. Chintagumpala M, Blaney S, Bomgaars L, et al. Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. J Clin Oncol 2004;22:4394-4400.
23. Herbst R, Madden T, Tran H, et al. Safety and pharmacokinetic effects of tnp-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: Evidence for activity in non-small-cell-lung-cancer. J Clin Oncol 2002;20:4440-4447.
24. Kerbel R, Kamen B. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Can 2004;4:423-436.
25. Jansen M, de Witt Hamer P, Witmer A, et al. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res Rev 2004;45:143-163.
26. Drevs J, Fakler J, Eisele S, et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004;24:1759-1763.
27. Emmenegger U, Man S, Shaked Y, et al. A comparative analysis of low-dose metronomic cyclophosphamide reveasl absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 2004;64:3994-4000.
28. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization of viability of circulating endothelial progenitor cells. Cancer Res 2003;63:4342-4346.
29. Kieran M, Turner C, Rubin J, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent of progressive cancer. J Pediatr Hematol Oncol 2005;27:573-581.